RxDoctor Payments Data

Adam Austin, MD

Pulmonary Disease · Gainesville, FLNPI 1629496658

Payments from drug & device makers

$1,568in general payments, 2019–2025

Across 16 payments — averaging $97.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$388
  • Boehringer Ingelheim$228
  • GSK$215
  • Merck$195
  • Insmed, Inc.$188
  • AstraZeneca$135
  • plus $219 from 2 others

What the payments were for

  • Food & beverage$1,38388%
  • Education$18512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,568 in reported general payments places this provider in the 35th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$118,350
Medicare patients
314
Services billed
898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter98$78,587
NucalaMepolizumab11$40,259
SymbicortBudesonide/Formoterol Fumarate38$11,461
Spiriva HandihalerTiotropium Bromide12$11,124
Combivent RespimatIpratropium/Albuterol Sulfate19$10,307
Spiriva RespimatTiotropium Bromide19$9,611
Breo ElliptaFluticasone/Vilanterol21$8,621
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$3,480
Albuterol Sulfate HfaAlbuterol Sulfate68$1,779
Wixela InhubFluticasone Propion/Salmeterol13$1,547
Fluticasone Propionate36$680
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate11$387
Azithromycin28$198
Prednisone35$125
Montelukast Sodium20$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta$215$127,467130 claims
Boehringer IngelheimCombivent Respimat, Spiriva Respimat$228$19,91838 claims
AstraZenecaSymbicort$135$11,46138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →